AR031078A1 - Compuesto acido (e)-4-[4-(5-metil-2-fenil-4-oxalilmetoxi)benziloxiimino]-4-fenilbutirico cristalino, composicion farmaceutica que lo comprende y su uso para fabricar esta ultima. - Google Patents
Compuesto acido (e)-4-[4-(5-metil-2-fenil-4-oxalilmetoxi)benziloxiimino]-4-fenilbutirico cristalino, composicion farmaceutica que lo comprende y su uso para fabricar esta ultima.Info
- Publication number
- AR031078A1 AR031078A1 ARP000105570A ARP000105570A AR031078A1 AR 031078 A1 AR031078 A1 AR 031078A1 AR P000105570 A ARP000105570 A AR P000105570A AR P000105570 A ARP000105570 A AR P000105570A AR 031078 A1 AR031078 A1 AR 031078A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutical composition
- crystals
- phenyl
- methyl
- manufacture
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 239000002253 acid Substances 0.000 title 1
- 239000013078 crystal Substances 0.000 abstract 5
- 206010012601 diabetes mellitus Diseases 0.000 abstract 2
- 230000008018 melting Effects 0.000 abstract 2
- 238000002844 melting Methods 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 102000005962 receptors Human genes 0.000 abstract 2
- 108020003175 receptors Proteins 0.000 abstract 2
- ULVDFHLHKNJICZ-JVCXMKTPSA-N (4z)-4-[[4-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]phenyl]methoxyimino]-4-phenylbutanoic acid Chemical compound CC=1OC(C=2C=CC=CC=2)=NC=1COC(C=C1)=CC=C1CO\N=C(\CCC(O)=O)C1=CC=CC=C1 ULVDFHLHKNJICZ-JVCXMKTPSA-N 0.000 abstract 1
- 206010003210 Arteriosclerosis Diseases 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 102000034527 Retinoid X Receptors Human genes 0.000 abstract 1
- 108010038912 Retinoid X Receptors Proteins 0.000 abstract 1
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 239000003614 peroxisome proliferator Substances 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
- 150000004492 retinoid derivatives Chemical class 0.000 abstract 1
- 238000000926 separation method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
El compuesto ácido (E)-4-[4-(5-metil-2-fenil-4-oxazolilmetoxi)benziloxiimino]-4-fenilbutírico de la formula (1), excepto aquellos cristales que tengan un punto de fusion de 126 degree C a 127 degree C. Dichos cristales presenta un punto de fusion de 136 degree C a 139 degree C y exhiben figuras de difraccion que tienen picos relevantes en las separaciones (valores d) comprendidos entre 17,5 y 6,0 angstrom, obtenidos mediante difraccion de cristales por rayos X de polvos. Composicion farmacéutica que comprende los cristales descriptos de utilidad como agente destinado a la prevencion o el tratamiento de: diabetes mellitus, hiperlipemia, disminucion de la tolerancia de glucosa, enfermedades inflamatorias y arterioesclerosis. Dicha composicion farmacéutica regula la funcion del receptor relacionado con los retinoides, actuando como ligando para los receptores activados con el proliferador de los peroxisomas y los receptores de retinoide X. Uso de los cristales del compuesto segun lo descripto, destinado a la fabricacion de una preparacion farmacéutica para la prevencion o el tratamiento de la diabetes mellitus.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP30834699 | 1999-10-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR031078A1 true AR031078A1 (es) | 2003-09-10 |
Family
ID=17979966
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP000105570A AR031078A1 (es) | 1999-10-29 | 2000-10-23 | Compuesto acido (e)-4-[4-(5-metil-2-fenil-4-oxalilmetoxi)benziloxiimino]-4-fenilbutirico cristalino, composicion farmaceutica que lo comprende y su uso para fabricar esta ultima. |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US6777435B1 (es) |
| EP (1) | EP1224178B1 (es) |
| KR (1) | KR100433885B1 (es) |
| CN (1) | CN1407975A (es) |
| AR (1) | AR031078A1 (es) |
| AT (1) | ATE243684T1 (es) |
| AU (1) | AU7958100A (es) |
| CA (1) | CA2388200A1 (es) |
| CL (1) | CL2000002938A1 (es) |
| CO (1) | CO5261530A1 (es) |
| DE (1) | DE60003577T2 (es) |
| HU (1) | HUP0203884A3 (es) |
| MY (1) | MY135840A (es) |
| NO (1) | NO20022007L (es) |
| PE (1) | PE20010761A1 (es) |
| PL (1) | PL364171A1 (es) |
| TW (1) | TW558554B (es) |
| WO (1) | WO2001032637A1 (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1277730A4 (en) * | 2000-03-28 | 2005-03-16 | HEMMER OF NEOVASCULARIZATION | |
| US20030045553A1 (en) | 2001-04-04 | 2003-03-06 | Bussolari Jacqueline C. | Combination therapy comprising glucose reabsorption inhibitors and PPAR modulators |
| EP1392326B1 (en) * | 2001-04-04 | 2009-09-09 | Ortho-McNeil-Janssen Pharmaceuticals, Inc. | Combination therapy comprising glucose reabsorption inhibitors and retinoid-x receptor modulators |
| CA2448741C (en) * | 2001-05-30 | 2010-06-22 | Kissei Pharmaceutical Co., Ltd. | Glucopyranosyloxypyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate therefor |
| TWI327462B (en) * | 2002-01-18 | 2010-07-21 | Sumitomo Chemical Co | Condensed heterocyclic sulfonyl urea compound, a herbicide containing the same, and a method for weed control using the same |
| US7556926B2 (en) | 2002-05-24 | 2009-07-07 | Takeda Pharmaceuticals Company Ltd. | Methods for screening insulin-sensitizing agents |
| US9132135B2 (en) * | 2004-09-24 | 2015-09-15 | University Of Maryland, Baltimore | Method of treating organophosphorous poisoning |
| EP1791904B1 (en) * | 2004-09-24 | 2014-08-27 | University of Maryland, Baltimore | Method of treating organophosphorous poisoning |
| JP2009507050A (ja) * | 2005-09-08 | 2009-02-19 | ガストロテック・ファルマ・アクティーゼルスカブ | 胆道ジスキネジーおよび／または胆道痛／不快の治療のためのｇｌｐ−１分子の使用 |
| TW201138843A (en) | 2009-12-18 | 2011-11-16 | Colgate Palmolive Co | Biguanide preservation of precipitated calcium carbonate |
| US11191755B2 (en) | 2014-01-17 | 2021-12-07 | Cornell University | Compositions and methods for providing cardioprotective effects |
| CA2937107C (en) | 2014-01-17 | 2020-12-22 | Cornell University | Methods of treating metabolic syndrome related conditions using retinoic acid receptor agonists |
| WO2018002673A1 (en) | 2016-07-01 | 2018-01-04 | N4 Pharma Uk Limited | Novel formulations of angiotensin ii receptor antagonists |
| KR102281228B1 (ko) | 2019-09-03 | 2021-07-22 | 신창수 | 과수나무의 가지지지용 파이프클램프 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9910371A (pt) | 1998-05-11 | 2001-01-09 | Takera Chemical Ind Ltd | Composto, composição farmacêutica, agente para controlar os receptores relacionados com a retinóide, processos de prevenção e terapia da diabetes mellitus, de prevenção e terapia da hiperlipemia, para acentuar uma sensibilidade à insulina, para melhorar uma resistência à insulina, de prevenção e terapia da tolerância à glicose prejudicada, de prevenção e terapia de uma doença inflamatória, de prevenção de uma esclerose arterial, e, uso do composto |
| EP1227081A4 (en) * | 1999-10-29 | 2004-08-11 | Takeda Chemical Industries Ltd | PROCESS FOR THE PREPARATION OF OXYMINOALKANOIC ACID DERIVATIVES |
-
2000
- 2000-10-23 TW TW089122215A patent/TW558554B/zh active
- 2000-10-23 AR ARP000105570A patent/AR031078A1/es unknown
- 2000-10-24 MY MYPI20005001A patent/MY135840A/en unknown
- 2000-10-26 EP EP00970081A patent/EP1224178B1/en not_active Expired - Lifetime
- 2000-10-26 CL CL2000002938A patent/CL2000002938A1/es unknown
- 2000-10-26 DE DE60003577T patent/DE60003577T2/de not_active Expired - Fee Related
- 2000-10-26 WO PCT/JP2000/007482 patent/WO2001032637A1/en not_active Ceased
- 2000-10-26 CA CA002388200A patent/CA2388200A1/en not_active Abandoned
- 2000-10-26 PL PL00364171A patent/PL364171A1/xx not_active Application Discontinuation
- 2000-10-26 CO CO00081698A patent/CO5261530A1/es not_active Application Discontinuation
- 2000-10-26 CN CN00816789A patent/CN1407975A/zh active Pending
- 2000-10-26 AU AU79581/00A patent/AU7958100A/en not_active Abandoned
- 2000-10-26 US US10/111,479 patent/US6777435B1/en not_active Expired - Fee Related
- 2000-10-26 HU HU0203884A patent/HUP0203884A3/hu unknown
- 2000-10-26 PE PE2000001148A patent/PE20010761A1/es not_active Application Discontinuation
- 2000-10-26 KR KR10-2001-7011003A patent/KR100433885B1/ko not_active Expired - Fee Related
- 2000-10-26 AT AT00970081T patent/ATE243684T1/de not_active IP Right Cessation
-
2002
- 2002-04-26 NO NO20022007A patent/NO20022007L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0203884A3 (en) | 2005-01-28 |
| KR20010102429A (ko) | 2001-11-15 |
| TW558554B (en) | 2003-10-21 |
| NO20022007D0 (no) | 2002-04-26 |
| CN1407975A (zh) | 2003-04-02 |
| HK1044536A1 (en) | 2002-10-25 |
| ATE243684T1 (de) | 2003-07-15 |
| NO20022007L (no) | 2002-06-24 |
| EP1224178A1 (en) | 2002-07-24 |
| PE20010761A1 (es) | 2001-08-01 |
| PL364171A1 (en) | 2004-12-13 |
| US6777435B1 (en) | 2004-08-17 |
| DE60003577T2 (de) | 2004-04-29 |
| CA2388200A1 (en) | 2001-05-21 |
| DE60003577D1 (de) | 2003-07-31 |
| CO5261530A1 (es) | 2003-03-31 |
| HUP0203884A2 (hu) | 2003-03-28 |
| KR100433885B1 (ko) | 2004-06-04 |
| AU7958100A (en) | 2001-05-14 |
| MY135840A (en) | 2008-07-31 |
| WO2001032637A1 (en) | 2001-05-10 |
| CL2000002938A1 (es) | 2009-05-15 |
| EP1224178B1 (en) | 2003-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR031078A1 (es) | Compuesto acido (e)-4-[4-(5-metil-2-fenil-4-oxalilmetoxi)benziloxiimino]-4-fenilbutirico cristalino, composicion farmaceutica que lo comprende y su uso para fabricar esta ultima. | |
| AR012998A1 (es) | Uso de un sensibilizador a insulina y de un agente antihiperglucemico para la preparacion de un medicamento y composicion farmaceutica que comprende dichosensibilizador y dicho agente. | |
| US8772273B2 (en) | Formulations and uses of retinoic acid receptor selective agonists | |
| AU8355998A (en) | Medicinal compositions with cholesterol-lowering effect | |
| BR0207880A (pt) | Formulação farmacêutica, processo para preparação da mesma e uso de formulação sólida | |
| ES2178430T3 (es) | Utilizacion de composiciones farmaceuticas gelificables en parodontologia. | |
| ATE546142T1 (de) | Salze und polymorphe einer wirkungsvollen antidiabetischen verbindung | |
| AR020001A1 (es) | COMPUESTOS ACTIVADORES DE hPPARGAMMA Y hPPARALFA, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN, METODO PARA EL TRATAMIENTO Y/O PREVENCION DE UNAENFERMEDAD MEDIADA POR LOS MISMOS, Y SU USO PARA LA ELABORACION DE UN MEDICAMENTO | |
| CA2476800A1 (en) | Crystals of glucopyranosyloxybenzyl benzene derivative | |
| CA2383140A1 (en) | Ppar.alpha. and ppar.gamma. inhibitors | |
| CA2377174A1 (en) | Oral administration forms for administering a fixed tramadol and diclofenac combination | |
| ATE173923T1 (de) | Oralanzuwendende flüssige arzneizubereitung enthaltend 2-(4-isobutylphenyl)propionsäure | |
| Patterson | Progress in the perforating dermatoses | |
| AR032138A1 (es) | Derivados de 6-hidroxi-indazol, una composicion oftalmica, y el uso de dichos derivados para la manufactura de un medicamento para el tratamiento de glaucoma | |
| AR005860A1 (es) | Compuestos heterociclicos aromaticos, composiciones farmaceuticas y cosmeticas que los contienen, y su utilización. | |
| WO2004011032A1 (ja) | 外用剤 | |
| ATE518526T1 (de) | Neue pharmazeutische zusammensetzung mit candesartan-cilexetil als lipophile kristalline substanz | |
| JP5714202B2 (ja) | 安定化酸素放出組成物 | |
| AR025030A1 (es) | Utilizacion de flupirtina para aliviar los dolores en las artropatias degenerativas en perros y gatos para la preparacion de un medicamento para eltratamiento de dichas afecciones | |
| AR016768A1 (es) | COMPOSICIoN FARMACÉUTICA DE 5-(4- (2-(N-METIL-N-(2-PIRIDIL) AMINO)ETOXI)BENCIL)TIAZOLIDIN-2-4-DIONA Y UN SECRETAGOGO DE INSULINA Y USO DE LA MISMA PARA PREPARACIoN DE MEDICAMENTOS | |
| JP2005505605A5 (es) | ||
| DE69414396D1 (de) | Acylphenylglycin-derivat und dieses als aktivbestandteil enthaltendes vorbeugungs -und heilmittel gegen durch erhöhte collagenaseaktivität verursachte krankheiten | |
| AR083893A1 (es) | Uso de una composicion farmaceutica que comprende (s) (3-(1-(1h-imidazol-4-il)etil)-2-metilfenil)metanol para preparar un medicamento topico de utilidad en la reduccion de la presion intraocular y articulo de manufactura correspondiente | |
| MA28036A1 (fr) | Utilisation d'oxcarbazepine dans le traitement de la douleur liee a la neuropathie diabetique et dans l'amelioration du sommeil | |
| JP2004507497A5 (es) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |